Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
← catalyst calendarSponsored by Xencor, Inc. (industry) · XNCR — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
28actual
Sites
17
Countries
Belgium, Greece, Malaysia +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-27 | actual | When the study began enrolling |
| Primary completion | 2025-12-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-29 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Nonsquamous Non-small Cell Lung Cancer
Interventions
- Combination product: Vudalimab + Carboplatin + Pemetrexed
- Combination product: Pembrolizumab + Carboplatin + Pemetrexed
Primary outcomes
what the primary-completion date above is the date OFPart 1: Recommended Phase 2 dose of vudalimab in combination with chemotherapy
measured Day 1 to Day 21
Part 2: Progression free survival
measured Day 1 to 2.5 years
Permalink · XNCR's whole pipeline · Catalyst calendar · Every registered study · What changed